Ad.p53-DC + nivolumab + ipilimumab

Ad.p53-DC + nivolumab + ipilimumab is an investigational combination immunotherapy regimen being evaluated for the treatment of relapsed or recurrent small cell lung cancer (SCLC). The regimen consists of **Ad.p53-DC** (also known as INGN-225), an autologous dendritic cell vaccine transduced with the full-length wild-type p53 gene via an adenoviral vector, alongside the immune checkpoint inhibitors **nivolumab** (an anti-PD-1 monoclonal antibody) and **ipilimumab** (an anti-CTLA-4 monoclonal antibody). The therapeutic rationale is based on the high frequency of p53 mutations in SCLC, which leads to the overexpression of p53 protein in tumor cells. The vaccine is designed to prime the immune system to recognize these p53-expressing cells, while the checkpoint inhibitors work to sustain the immune response by blocking inhibitory signals that tumors use to evade detection. This combination is primarily being investigated in Phase 2 clinical trials led by the H. Lee Moffitt Cancer Center and Research Institute.

Brand names

OpdivoYervoy

Other names

p53 vaccine + nivolumab + ipilimumabAd-p53 transduced dendritic cell vaccine + nivolumab + ipilimumab